1. Evidence of histologically or cytologically confirmed diagnosis of locally advanced or
metastatic ALK positive NSCLC where ALK status has been previously established by the
Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe
Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).
2. Subject should have:
1. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;
2. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib,
with or without prior crizotinib.
3. Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study
4. All Subjects must have at least 1 measurable extracranial target lesion according to
RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:
1. Asymptomatic: either not currently requiring corticosteroid treatment, or on a
stable or decreasing dose of 10 mg QD prednisone or equivalent; or
2. Previously diagnosed and treatment has been completed with full recovery from the
acute effects of radiation therapy or surgery prior to enrollment, and if
corticosteroid treatment for these metastases has been withdrawn for at least 4
weeks with neurological stability.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.
6. Age 18 years (or 20 years as required by local regulation).
7. Adequate bone marrow functions:
1. Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;
2. Platelets 100,000/mm3 or 100 x 109/L;
3. Hemoglobin 9 g/dL.
8. Adequate pancreatic function:
1. Serum total amylase 1.5 x upper limit of normal (ULN);*
2. Serum lipase 1.5 x ULN. *if total amylase >1.5 x ULN, but pancreatic amylase is
within the ULN, then subject may be enrolled.
9. Adequate renal function:
a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as
calculated using the method standard for the institution.
10. Adequate liver function:
1. Total serum bilirubin 1.5 x ULN;
2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN
(5.0 x ULN in case of liver metastases).
11. Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or
to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a
safety risk for the subject.
12. Serum or urine pregnancy test (for females of childbearing potential) negative at
screening. Female subjects of non childbearing potential must meet at least 1 of the
1. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause (which may be confirmed with a serum follicle stimulating
hormone (FSH) level confirming the postmenopausal state if appropriate;
2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
3. Have medically confirmed ovarian failure. All other female subjects (including
female subjects with tubal ligations) are considered to be of childbearing
13. Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
14. Willing and able to comply with the study scheduled visits, treatment plans,
laboratory tests, and other procedures.
Subjects with any of the following characteristics/conditions will not be included in the
1. More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic
If disease recurred/relapsed within the adjuvant chemotherapy treatment or
after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is
considered as the first line systemic chemotherapy to the disease.
2. Systemic anti cancer therapy completed within a minimum of 5 half lives of study
3. Prior therapy with an antibody or drug specifically targeting T cell co stimulation or
immune checkpoint pathways, including, but not limited to, anti programmed cell death
protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti
PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T
lymphocyte associated antigen 4 (anti CTLA 4) antibody.
4. Known epidermal growth factor receptor (EGFR) activating mutations; known prior
therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK
5. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port
insertion) are not excluded, but sufficient time should have passed for adequate wound
6. Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have
been completed at least 48 hours prior to enrollment. Stereotactic or partial brain
irradiation must have completed at least 2 weeks prior to enrollment. Whole brain
irradiation must have completed at least 4 weeks prior to enrollment.
7. Spinal cord compression unless the subject has good pain control attained through
therapy, and there is complete recovery of neurological function for the 4 weeks prior
8. Gastrointestinal abnormalities, including inability to take oral medication;
requirement for intravenous alimentation; prior surgical procedures affecting
absorption including total gastric resection or lap band; active inflammatory
gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease;
treatment for active peptic ulcer disease in the past 6 months; malabsorption
9. Known prior or suspected severe hypersensitivity to lorlatinib or any component in the
formulation; known prior therapy with lorlatinib.
10. Active and clinically significant bacterial, fungal, or viral infection including
hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus
(HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
11. Clinically significant cardiovascular disease (both arterial and venous) and non
vascular cardiac conditions, (active or within 3 months prior to enrollment, which may
include, but not are limited to:
- Arterial disease such as cerebral vascular accident/stroke (including transient
ischemic attack -TIA), myocardial infarction, unstable angina;
- Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary
- Nonvascular cardiac disease such as congestive heart failure (New York Heart
Association Classification Class ? II), second degree or third degree
atrioventricular block (unless paced) or any AV block with PR interval >220 msec;
- Ongoing cardiac dysrhythmias of CTCAE Grade ?2, uncontrolled atrial fibrillation
of any grade, bradycardia defined as such as long distance runners, etc.), machine read electrocardiogram (ECG) with
QTc >470 msec, or congenital long QT syndrome.
12. Subject with predisposing characteristics for acute pancreatitis according to
investigator judgment, including but not limited to uncontrolled hyperglycemia,
current gallstone disease, in the last month prior to enrollment.
13. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
fibrosis or interstitial lung disease including a history of pneumonitis,
hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,
obliterative bronchiolitis and pulmonary fibrosis.
14. Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or
localized and presumed cured prostate cancer or any in situ cancer which does not
currently require treatment) within the last 3 years prior to enrollment.
15. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt
whether a food or a drug falls into any of the above categories) within 12 days prior
to the first dose of administration of lorlatinib:
1. Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or
grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos],
boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole,
ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or
paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir,
troleandomycin, and voriconazole). The topical use of these medications (if
applicable), such as 2% ketoconazole cream, is allowed;
2. Known CYP3A substrates with narrow therapeutic index, such as astemizole*,
terfenadine*, cisapride*, pimozide, quinidine, tacrolimus, cyclosporine,
sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids
(ergotamine, dihydroergotamine) (*withdrawn from US market);
3. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane,
phenytoin, rifampin, St. John's Wort);
4. Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg,
16. Other severe acute or chronic medical or psychiatric condition, including recent
(within the past year) or active suicidal ideation or behavior, or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator and/or the sponsor, would make
the subject inappropriate for entry into this study.
17. Subject who are investigational site staff members directly involved in the conduct of
the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are Pfizer employees, including their family members,
directly involved in the conduct of the study.
18. Participation in other studies involving investigational drug(s) within 2 weeks prior
to study entry and/or during study participation.
19. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and
female subjects of childbearing potential who are unwilling or unable to use a highly
effective method of contraception as outlined in this protocol for the duration of the
study and for at least 97 days if male or 21 days if female, after the last dose of